Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anebulo Pharmaceuticals Inc ANEB

Healthcare
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the... see more

Recent & Breaking News (NDAQ:ANEB)

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Business Wire 10 days ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Business Wire September 25, 2024

Lifecore Biomedical Announces Cooperation Agreement with 22NW

GlobeNewswire July 1, 2024

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Business Wire May 15, 2024

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Business Wire February 13, 2024

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Business Wire November 14, 2023

Anebulo Pharmaceuticals Announces New CEO

Business Wire October 6, 2023

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Business Wire October 6, 2023

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Business Wire September 20, 2023

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Business Wire August 30, 2023

Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension

Business Wire August 21, 2023

Sidoti Events, LLC's Virtual August Micro-Cap Conference

Accesswire August 15, 2023

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

PR Newswire May 11, 2023

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

PR Newswire March 28, 2023

Sidoti's Small-Cap Virtual March Conference

Accesswire March 20, 2023

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

PR Newswire March 8, 2023

Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap Conferences

Accesswire February 14, 2023

 Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Business Wire February 10, 2023

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Business Wire January 9, 2023

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Business Wire November 10, 2022